ArticleMolecular biology reports2013
Inhibition of focal adhesion kinase induces apoptosis in human gastric carcinoma cells (SGC-7901).
Article in Molecular biology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance.Oncology letters · 2020Article
- Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Gastric Cancer: Identification of microRNAs Inhibiting Druggable Targets and Mediating Efficacy in PreclinicalCancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase protein, acts as an early modulator of integrin signaling cascade, regulating basic cellular functions. In transformed cells, unopposed FAK signaling has been considered to promote tumor growth, progression and metastasis. The aim of this study was to assess the role of FAK in human gastric carcinoma cells. SGC-7901 cells were transfected with PGPU6/GFP/shNC (shNC), PGPU6/GFP/FAK-299 (shRNA-299), respectively. Expression of FAK was detected by real-time PCR and Western blots. MTT assay was used to examine changes in cell proliferation. Cell apoptosis was analyzed by flow cytometry. The expression of caspase-3, -9 was measured by Western blots. The expression of FAK in SGC-7901 cells significantly decreased in shRNA-299 group contrast to the control group (P < 0.01). Cells proliferation was inhibited by shRNA-299 and shRNA-299 + cisplatin, and the effects were clearly enhanced when cells treated with the anticancer agents. The level of cell apoptosis in shRNA-299 and shRNA-299 + cisplatin group was higher than in the control group (P < 0.01). The current data support evidence that down-regulation of FAK could induce human gastric carcinoma cells (SGC-7901) apoptosis through the caspase-dependent cell death pathway. Inhibition of the kinases may be important for therapies designed to enhance the apoptosis in gastric carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.